Formulation and Evaluation of Biodegradable Polymeric Nanoparticles of Doxorubicin for Targeted Cancer Therapy

Cancer remains a major global health challenge and requires therapeutic strategies capable of maximizing antitumor activity while limiting injury to normal tissues. Conventional chemotherapy is often constrained by nonspecific biodistribution, narrow therapeutic windows, systemic adverse effects, and biological barriers that restrict drug exposure at tumor sites. Nanomedicine has therefore attracted substantial interest because nanoscale carriers can alter the physicochemical and pharmacokinetic behavior of conventional anticancer agents.

Doxorubicin hydrochloride is an anthracycline antibiotic and cytotoxic drug that acts primarily through DNA intercalation, inhibition of topoisomerase II, and generation of reactive oxygen species. It is used in the treatment of breast cancer, lymphomas, sarcomas, leukemias, and several other malignancies. Despite its effectiveness, cumulative cardiotoxicity is a major dose-limiting concern. Free doxorubicin also undergoes rapid distribution and clearance, and its exposure to normal tissues contributes to systemic toxicity.

Polymeric nanoparticles prepared from biodegradable polymers such as PLGA are attractive because the polymer undergoes hydrolytic degradation into lactic acid and glycolic acid, which enter normal metabolic pathways. The carrier can encapsulate or associate with a drug and release it through diffusion, polymer hydration, and polymer erosion. Particle size, surface characteristics, polymer molecular weight, drug-to-polymer ratio, surfactant concentration, and preparation conditions influence the final formulation.

Targeted delivery can be considered at two levels. Passive targeting exploits the altered vascular and lymphatic characteristics of tumors, although the enhanced permeability and retention (EPR) effect is heterogeneous in human tumors. Active targeting involves attaching ligands such as antibodies, peptides, aptamers, or receptor-binding molecules to the nanoparticle surface. The present work focuses on development and characterization of a biodegradable polymeric nanoparticle platform and provides a basis for subsequent active-targeting studies.

2. AIM AND OBJECTIVES.

Aim: To formulate and evaluate biodegradable polymeric nanoparticles of doxorubicin for improved and potentially targeted anticancer drug delivery.

• To select a suitable biodegradable polymeric carrier and establish a reproducible nanoparticle preparation method.

• To evaluate drug-polymer compatibility using suitable preformulation techniques.

• To prepare nanoparticle batches by a solvent-based or emulsion-based method and optimize critical formulation variables.

• To characterize optimized nanoparticles for particle size, PDI, zeta potential, morphology, drug entrapment efficiency, and drug loading.

• To investigate the in-vitro release profile of doxorubicin from the optimized nanoparticles.

• To fit the release data to mathematical kinetic models and identify the probable release mechanism.

• To assess preliminary physical stability and identify requirements for future in-vitro and in-vivo targeting studies.

3. MATERIALS AND METHODS

3.1 Materials

Materials should be pharmaceutical/research grade and their certificate of analysis, molecular weight, polymer lactideglycolide ratio, and residual-solvent specifications should be recorded. Because doxorubicin is a hazardous cytotoxic drug, all preparation and analytical procedures should be performed under institutionally approved containment and waste-disposal procedures.

3.2 Preformulation Studies

Drug-polymer compatibility should be assessed before formulation. Fourier-transform infrared spectroscopy (FTIR) may be used to compare characteristic functional groups of the drug, polymer, and physical mixture. Where appropriate, differential scanning calorimetry (DSC) and/or powder X-ray diffraction (PXRD) can be used to investigate changes in thermal behavior and crystallinity. These studies help identify major chemical incompatibilities and changes in the physical state of the drug.

3.3 Preparation of Polymeric Nanoparticles

A representative nanoprecipitation/emulsion-solvent evaporation approach can be used. PLGA is dissolved in a suitable volatile organic phase and doxorubicin is incorporated using a method appropriate to its salt form and physicochemical properties. The organic phase is introduced into an aqueous PVA phase under controlled stirring or homogenization to generate an emulsion/nanodispersion. The organic solvent is removed under reduced pressure or controlled stirring, followed by collection of nanoparticles through centrifugation or an equivalent validated separation step. The particles may be washed to remove free drug and residual stabilizer and may then be redispersed or lyophilized with a suitable cryoprotectant.

3.4 Experimental Design

Optimization should preferably use a design-of-experiments (DoE) approach rather than changing one factor at a time. Independent variables may include drug-to-polymer ratio, stabilizer concentration, and mixing intensity, while responses may include particle size, PDI, entrapment efficiency, drug loading, and release characteristics. The final batch should be selected using predefined acceptance criteria and desirability-based optimization.

3.5 Characterization of Nanoparticles

Particle size and PDI

Dynamic light scattering (DLS) should be used after suitable dilution in a validated dispersion medium. Particle size is reported as mean diameter and PDI as a measure of distribution breadth.

Zeta potential

Electrophoretic light scattering can be used to estimate surface charge. The value provides information about electrostatic stabilization and surface properties.

Morphology

Transmission electron microscopy (TEM) or scanning electron microscopy (SEM) may be used to examine particle shape and surface morphology.

Entrapment efficiency

Nanoparticle-associated drug is separated from free drug, and doxorubicin is quantified by a validated UV-visible or chromatographic analytical method. Entrapment efficiency is calculated as: EE% = [(total drug − free drug)/total drug] × 100.

Drug loading

Drug loading is calculated as: DL% = [drug associated with nanoparticles/weight of recovered nanoparticles] × 100.

In-vitro release

A suitable dialysis or diffusion-based method can be used under sink conditions with a validated release medium and controlled temperature. Samples are withdrawn at predetermined intervals and replaced with fresh medium.

Release kinetics

Zero-order, first-order, Higuchi, and Korsmeyer–Peppas models can be compared. Model selection should consider goodness of fit and the physical plausibility of the mechanism.

Stability

Changes in appearance, particle size, PDI, zeta potential, drug content, and release behavior should be monitored under selected storage conditions.

4. RESULTS AND DISCUSSION

The following results are an illustrative example for manuscript formatting and interpretation. They must be replaced by actual experimental observations before submission as an original research article.

An optimized nanosystem in the approximate 100–250 nm range would generally be considered suitable for further nanomedicine investigation, although particle size alone does not establish tumor targeting. The illustrative PDI indicates a relatively narrow distribution. A negative zeta potential may contribute to colloidal stability depending on the formulation environment, but stability should be confirmed experimentally rather than inferred from zeta potential alone.

An entrapment efficiency above 80% in the illustrative dataset indicates that most of the drug was associated with the polymeric carrier. Actual doxorubicin loading may vary substantially with formulation method because the drug is hydrophilic and its interaction with a hydrophobic polymer such as PLGA can be challenging. Double-emulsion or ion-pairing approaches may therefore be explored if the initial method gives inadequate loading.

4.1 Illustrative In-vitro Release Profile

The illustrative profile demonstrates an initial limited burst followed by sustained release. The early release may be associated with drug located near or on the particle surface, whereas later release can result from diffusion through hydrated polymer domains and progressive PLGA degradation. A suitable formulation should balance sustained release with adequate drug availability; excessively slow release may reduce therapeutic exposure.

4.2 Release Kinetics